Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Observational

Body Representation and Neuropathic Pain in Spinal Cord Injury

NCT06794242 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2025-04
Last updated
2025-01-27

Condition(s) studied

Spinal Cord Injury

Investigational drug(s) / intervention(s)

Body representation

Body representation: All the participants (controls and patients) in the study will follow the same experimental procedure, which consists of a single virtual reality session involving the estimation of leg length and an object.

Study summary

Chronic pain is one of the main complications of spinal cord injury, has a very negative impact on quality of life, and persists over time despite the use of analgesic treatments. Several types of pain are possible in patients with spinal cord injury, and neuropathic pain (pain caused by damage to the spinal cord, in this case) is one of the most difficult to treat, even with medication. Following an injury to the spinal cord, it is possible for the representation of the body to change as a result of sensorimotor deficits, prolonged changes in body posture and altered mobility. At present, the causes of chronic pain after spinal cord injury remain poorly understood and debated, but one hypothesis suggests that changes in body representation may play a key role in the development or worsening of neuropathic pain. To test this hypothesis, we will assess the perception of spinal cord injured patients (and a group of controls) of the size of their legs using a virtual reality device. This measurement will enable us to examine whether under- or over-estimation of leg length correlates with the presence of neuropathic pain in patients. Chronic pain in people with spinal cord injury is associated with an increased risk of stress, depression and anxiety, and understanding and treating neuropathic pain in people with spinal cord injury is a major issue in their management.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria : Patients group: * Men and women between the ages of 18 and 65; * Have normal or corrected eyesight; * Have a spinal cord lesion resulting in total or partial loss of tactile and proprioceptive sensitivity and motor skills in the lower limbs. * have given their free and informed consent in writing, after having been informed orally and in writing of the study's progress. Control group: * Men and women between 18 and 65 years of age * Have normal or corrected eyesight * Have given their free and informed written consent after having been informed orally and in writing of the course of the study. Exclusion Criteria : Patients Group: * People with a diagnosis of Eating Disorder * People with a diagnosis of a psychiatric disorder that can modify body representations * People who suffer from physiological discomfort when using gaming headsets or virtual reality * People under psychiatric care * Illiterate people * Pregnant women, women in labour or breastfeeding mothers * Persons deprived of their liberty by judicial or administrative decision * Adults under legal protection (guardianship, curatorship) * Persons not affiliated to a social security scheme or beneficiaries of a similar scheme Control group: * People with an eating disorder diagnosis * People diagnosed with psychiatric disorders that can modify body representations * People who suffer from physiological discomfort when using gaming headsets or virtual reality * People under psychiatric care * Illiterate people * People with functional neurological motor disorders and/or partial or complete deficits and/or abnormal movements * People with sensitivity problems in the lower limbs * Pregnant women, women in labour or breastfeeding mothers * Persons deprived of their liberty by judicial or administrative decision * Persons admitted to a health or social establishment for purposes other than research * Adults under legal protection (guardianship, curatorship) * Persons not affiliated to a social security scheme or beneficiaries of a similar scheme

Primary outcome measure(s)

  • Différences in leg length estimation between controls and patients in the length representation test. — From baseline up to a maximum of 2 weeks
    We will measure the difference between the representation of the length of the lower limbs of controls and spinal cord injured patients. This difference will be assessed using the Point of Subjective Equality (defined as the size of the avatar's legs perceived by the participant as corresponding to the length of their legs) with a two-sample Mann Whitney test (two-tailed) (controls and patients)

Trial sites (2)

FacilityCityRegionStatus
Pierre Wertheimer Neurological Hospital Bron France
Henry Gabrielle Hospital Saint-Genis-Laval France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06794242 on ClinicalTrials.gov ↗ ← All trials in France